HOOK (HOOKIPA Pharma) EBIT: $-56.11 Mil (TTM As of Jun. 2025)


HOOK HOOKIPA Pharma Inc HOOK
49 GF Score
Price $1.15
GF Value $2.78
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is HOOKIPA Pharma EBIT?

HOOKIPA Pharma HOOK 49 EBIT is $-56.11 Mil as of Jun. 2025. GuruFocus rates HOOK with a GF Score™ of 49/100 and a GF Value™ of $2.78 (Possible Value Trap). The stock has 6 warning signs investors should review.

HOOKIPA Pharma's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2025 was $-1.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2025 was $-56.11 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. HOOKIPA Pharma's annualized ROC % for the quarter that ended in Jun. 2025 was -376.04%. HOOKIPA Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was -1,182.78%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. HOOKIPA Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2025 was 288.47%.

HOOKIPA Pharma  (OTCPK:HOOK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

HOOKIPA Pharma's annualized ROC % for the quarter that ended in Jun. 2025 is calculated as:

ROC % (Q: Jun. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Jun. 2025 ))/ count )
=-26.048 * ( 1 - 0% )/( (8.288 + 5.566)/ 2 )
=-26.048/6.927
=-376.04 %

where

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=61.256 - 12.692 - ( 40.276 - max(0, 16.637 - 60.091+40.276))
=8.288

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=52.706 - 12.91 - ( 34.23 - max(0, 13.159 - 51.675+34.23))
=5.566

Note: The Operating Income data used here is four times the quarterly (Jun. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

HOOKIPA Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2025  Q: Jun. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-7.144/( ( (0.686 + max(-4.272, 0)) + (0.522 + max(-4.066, 0)) )/ 2 )
=-7.144/( ( 0.686 + 0.522 )/ 2 )
=-7.144/0.604
=-1,182.78 %

where Working Capital is:

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.545 + 0 + 11.508) - (12.692 + 3.633 + 0)
=-4.272

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.903 + 0 + 7.942) - (12.91 + 0 + 0.0010000000000012)
=-4.066

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

HOOKIPA Pharma's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2025 )
=-56.11/-19.451
=288.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma EBIT Related Terms

HOOKIPA Pharma EBIT Historical Data

* Premium members only.

The historical data trend for HOOKIPA Pharma's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HOOKIPA Pharma EBIT Chart

HOOKIPA Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial -43.30 -74.77 -64.00 -80.90 -43.61

HOOKIPA Pharma Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.10 -13.84 -25.06 -15.43 -1.79

HOOK vs LNAI, ZEOX, GDTC: EBIT Comparison

For the Biotechnology subindustry, HOOKIPA Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HOOKIPA Pharma EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HOOKIPA Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HOOKIPA Pharma's EV-to-EBIT falls into.


HOOK
49GF Score
HOOKIPA Pharma Inc HOOK
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HOOKIPA Pharma EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-56.11 Mil mean?
HOOKIPA Pharma (HOOK) has a EBIT of $-56.11 Mil as of Jun. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HOOKIPA Pharma.
Is HOOKIPA Pharma's EBIT too high?
HOOKIPA Pharma's current EBIT is $-56.11 Mil. Overall, HOOKIPA Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HOOKIPA Pharma's EBIT compare to LNAI and ZEOX?
HOOKIPA Pharma's EBIT of $-56.11 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on HOOKIPA Pharma. HOOKIPA Pharma's current EBIT is $-56.11 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOOKIPA Pharma stock overvalued right now?
Based on GuruFocus' analysis, HOOKIPA Pharma (HOOK) is currently considered Possible Value Trap. The stock's GF Value™ is $2.78, compared to a current price of $1.15 — trading 58.6% below its estimated fair value. The current EBIT is $-56.11 Mil. HOOKIPA Pharma's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For HOOKIPA Pharma (HOOK), the current EBIT is $-56.11 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HOOKIPA Pharma (HOOK) Overvalued in 2026?

Based on GuruFocus' analysis, HOOKIPA Pharma stock appears to be undervalued. The current stock price of $1.15 is trading 58.6% below its estimated GF Value™ of $2.78. GuruFocus considers HOOKIPA Pharma to be Possible Value Trap.

Key valuation signals for HOOK:

  • EBIT: $-56.11 Mil
  • GF Value™: $2.78 vs. price of $1.15 (58.6% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the HOOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HOOKIPA Pharma Business Description

Address 350 Fifth Avenue, 72nd Floor, Suite 7240, New York, NY, USA, 10118
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company's product candidates are designed to induce specific, robust and durable CD8+ T cells and antibodies to eliminate cancers and serious infectious diseases. Its pipeline includes biological therapies for oncology, targeting human papillomavirus type 16-positive (HPV16+) cancers, KRAS mutated cancers, and other targets. In addition, It is also focused to develop therapies that are intended to provide functional cures for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).
49GF Score

Get the complete analysis for HOOK

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.15
Price
$2.78
GF Value